

ALIMERA SCIENCES INC  
Form 8-K  
October 18, 2013

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 8-K  
CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934  
Date of Report (Date of earliest event reported): October 18, 2013  
ALIMERA SCIENCES, INC.  
(Exact name of registrant as specified in its charter)

|                                                   |                          |                                   |
|---------------------------------------------------|--------------------------|-----------------------------------|
| Delaware                                          | 001-34703                | 20-0028718                        |
| (State or other Jurisdiction of<br>Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |

|                                                           |            |
|-----------------------------------------------------------|------------|
| 6120 Windward Parkway<br>Suite 290<br>Alpharetta, Georgia | 30005      |
| (Address of Principal Executive Offices)                  | (Zip Code) |

Registrant's telephone number, including area code: (678) 990-5740

Not Applicable

(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 8.01. Other Events.

On October 18, 2013, Alimera Sciences, Inc. (the Company) issued a press release announcing, among other things, the issuance by the U.S. Food and Drug Administration of a Complete Response Letter regarding the Company's New Drug Application for ILUVIEN. A copy of the press release is attached as Exhibit 99.1 hereto and is incorporated by reference herein.

---

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

| Exhibit<br>No. | Description                                                    |
|----------------|----------------------------------------------------------------|
| 99.1           | Press Release of Alimera Sciences, Inc. dated October 18, 2013 |

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ALIMERA SCIENCES, INC.

Dated: October 18, 2013

By: /s/ RICHARD S. EISWIRTH, JR.  
Name: Richard S. Eiswirth, Jr.  
Title: Chief Operating Officer and  
Chief Financial Officer